Biogen Up 40% Premarket on Revived Alzheimer's Drug
October 22 2019 - 8:17AM
Dow Jones News
By Colin Kellaher
Shares of Biogen Inc. (BIIB) surged more than 40% in premarket
trading Tuesday after the company said it would pursue regulatory
approval for aducanumab, an investigational treatment for early
Alzheimer's disease that had previously been deemed a failure.
Biogen and partner Eisai & Co. (4523.TO) ended two
late-stage studies of aducanumab earlier this year after
determining the drug likely wouldn't help patients, but the biotech
on Tuesday said a new analysis of a larger dataset from the studies
showed aducanumab reduced clinical decline in patients with early
Alzheimer's disease.
Analysts at Citigroup said that while remains to be seen if
aducanumab could be approved and become commercially successful, a
model of $3 billion to $4 billion of peak sales in the indication
yields a Biogen fair value of $345 to $375 a share.
Biogen shares, which closed Monday at $223.51, were up 42%, to
$317.74, in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2019 08:02 ET (12:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024